Not medical advice. Talk to your provider before using any peptide. Full disclaimer
BPC-157 vs GHK-Cu
Peptide Schedule Research TeamReviewed Oct 13, 202618 Citations
BPC-157 and GHK-Cu are both called healing peptides, but their evidence points different ways. BPC-157's case rests mostly on rats, plus five small human studies. GHK-Cu has small human trials too, almost all of creams and gels on the skin.
A 2025 systematic review by Vasireddi's group (PMID 40756949) screened 544 papers on BPC-157. Thirty-six met inclusion criteria. Thirty-five were preclinical studies. One was clinical. That ratio says a lot about where the science stands right now. The review's orthopaedic search ran through June 3, 2024, and kept studies of mechanism, musculoskeletal outcomes, metabolism and safety. FDA's July 2026 briefing searched every use and counted five small human studies, two known only from meeting abstracts. The BPC-157 peptide (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) from a protective protein in human gastric juice. In animal and cell studies, it promotes tissue repair through angiogenesis (VEGF-driven blood vessel growth), nitric oxide modulation, and FAK-paxillin pathway activation in tendon cells. One property separates it from most peptides: it stays stable in human gastric juice (PMID 38675421). In rats, oral dosing works for gut injuries; no human study has measured how much of an oral dose is absorbed. Animal data is reproducible across labs and species. Healing acceleration has been confirmed in tendons, ligaments, muscles, nerves, corneas, and intestinal ulcers. A 2024 intravesical case series (12 patients (n=12) with interstitial cystitis) reported 80 to 100 percent symptom resolution. A 2025 IV pilot by Lee and Burgess confirmed tolerability up to 20 mg intravenous in two adults. Community data adds a different kind of evidence. Across r/Peptides, ExcelMale, and Longecity, users have reported steady outcomes for years. Pain reduction and improved mobility within 1 to 3 weeks for soft tissue injuries. Gut symptom relief within days on oral dosing. Faster post-surgical recovery. The community figured out the standard protocol before the researchers caught up. 250 mcg subcutaneous twice daily, near the injury, for 4 to 6 weeks. BPC-157 has no FDA approval. The FDA placed it on the Category 2 bulk drug substance list in 2023, blocking compounding. Its nominators withdrew it, and FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn. FDA's Pharmacy Compounding Advisory Committee (PCAC) discussed BPC-157 on July 23, 2026. No FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today. Compared to TB-500, BPC-157 targets local tissue repair near the injection site through angiogenesis and NO modulation. TB-500 works systemically regardless of injection location. The two are commonly paired in a 1:1 ratio for combined local and systemic coverage.
View full guide →At least 4,000 human genes. That's how many GHK-Cu raises or lowers in gene expression data analyzed by Pickart's group (PMID 29986520, 26236730). The GHK-Cu peptide (glycyl-L-histidyl-L-lysine copper(II), also written GHK:Cu or copper tripeptide-1) is a naturally occurring copper peptide found in human plasma, saliva, and urine. Plasma levels sit around 200 ng/mL at age 20 and drop to roughly 80 ng/mL by age 60. The mechanism is broad. GHK-Cu upregulates collagen I, III, and V synthesis, boosts elastin and decorin production, and recruits immune and endothelial cells to damaged tissue. The copper ion itself is required for enzymatic processes in wound remodeling. In 2024, Bian and colleagues confirmed anti-fibrotic activity in silicosis mice and found lower plasma GHK in silicosis patients (PMID 38879894). Its research now reaches past skin. In practice, two routes dominate. Topical formulations (1 to 3% concentration) have cosmetic safety data going back decades; small clinical trials (n = 41 to 71) showed improved skin density and fine line reduction. Injectable use (0.5 to 2 mg/day subcutaneous) has no published dose-finding trial in humans but has one of the largest community evidence bases of any anti-aging peptide. Reports across r/Peptides, r/Biohackers, and practitioner networks describe improved skin firmness by weeks four to six; sentiment runs at 4.2 out of 5. The honest limitation: all mechanistic data is in vitro or murine. Pro-angiogenic activity flagged by the NCI raises an unresolved theoretical oncology concern. GHK-Cu is classified as research-only and is not FDA-approved for any indication.
View full guide →At a Glance
| Attribute | ||
|---|---|---|
| Category | Healing & Recovery | Anti-Aging |
| Safety Grade | C | B |
| Half-Life | 15.2 min IV in rats, 5.3 min in dogs; under 30 min after IM; no human data | ~1 hour |
| Route | Subcutaneous (near injury) or Oral | Subcutaneous or Topical |
| Vial Sizes | 5 mg, 10 mg | 5 mg, 50 mg |
| Beginner Dose | 250 mcg 2x Daily | 1 mg Daily |
| Moderate Dose | 500 mcg Daily | 2 mg Daily |
| Aggressive Dose | 500 mcg 2x Daily | 3 mg Daily |
| Dosing Source | Community | Community |
| Side Effects | FDA's 2026 review counted five small human studies, about 80 people in all; the three published pilots cover about 30 of them. The published literature calls it well-tolerated. That is accurate for what it covers; it just does not cover much. At standard doses (250 to 500 mcg per day), most users report no problems. The side effect picture changes above 500 mcg per day and in people on SSRIs or SNRIs. Anxiety and panic attacks are the most commonly reported serious community side effects. In rats, BPC-157 interacts with dopamine and adrenergic systems (Sikiric and colleagues, PMID 9073154) and shifts brain serotonin synthesis (PMID 15531385). Users with pre-existing anxiety disorders and those on serotonergic medications report the highest rates of this effect. Heart palpitations show up repeatedly in community reports, typically in the first few days of a cycle. They tend to clear within a week. Mood changes, including anhedonia, irritability, and a vague sense of feeling "off," affect a subset of users. These track with the dopaminergic and serotonergic modulation in preclinical work. They are more common at higher doses. Insomnia and vivid dreams come up occasionally. Brain fog above 750 mcg per day appears in community reports with no preclinical correlate. Nausea is more frequent with oral dosing. Some users report zero effect. Product quality is the usual explanation. Finnrick Analytics tested 450 samples from 64 companies; purity ranged from 82 to 100 percent, with 8 percent of samples containing endotoxin contamination. Contraindications: pregnancy and breastfeeding (no reproductive data), active cancer or cancer history (angiogenesis could theoretically feed tumor growth), children under 18 (no pediatric data). The SSRI/SNRI interaction risk warrants a conversation with your prescriber. | The most serious concern with GHK-Cu is its pro-angiogenic activity. The NCI flagged this years ago: a peptide that promotes new blood vessel formation could, in theory, support tumor vascularization. No human case has confirmed this, but no study has ruled it out either. Anyone with an active malignancy should not use GHK-Cu without oncologist clearance. Copper toxicity is the second concern worth taking seriously. Continuous long-term use without lab monitoring creates an accumulation risk. Wilson's disease, hemochromatosis, and any copper metabolism disorder are absolute contraindications. Symptoms of copper excess include nausea, metallic taste, and jaundice; if these appear, stop immediately and get serum copper checked. Published side effects in topical trials are mild. Skin irritation, redness, and occasional contact sensitivity at higher concentrations. The more interesting adverse pattern comes from the community: "copper uglies." This is paradoxical skin worsening (sagging, accelerated wrinkling) caused by MMP-1 matrix metalloproteinase upregulation outpacing collagen synthesis. It happens most often with topical overuse or aggressive post-microneedling application. The fix is simple: drop to 1% concentration and wait 48 to 72 hours after microneedling before applying. Injectable side effects are dominated by injection site reactions. Burning and stinging from the copper ions is the number one complaint in community threads. Diluting with more bacteriostatic water, using a 31-gauge needle, and applying a cold compress for 60 seconds post-injection helps. Site rotation matters; no location should get more than one injection per week. Poor rotation leads to lipodystrophy (localized fat atrophy), which is harder to reverse than it sounds. At doses above 1.5 mg/day, some users report nausea and metallic taste. These are dose-dependent and resolve with reduction. Reconstituted stability is limited to two to three weeks refrigerated. Potency drops 15 to 30% by week four according to community tracking. The mcg versus mg calculation error is a real hazard for beginners; GHK-Cu vials are labeled in mg but doses are discussed in mcg. 1 mg equals 1,000 mcg. Getting this wrong by a factor of 1,000 is not theoretical; it's the most common beginner mistake in the community. Contraindications: Wilson's disease or copper metabolism disorders. Known hypersensitivity to GHK-Cu or copper compounds. Pregnancy or breastfeeding (no safety data). Hemochromatosis. Active malignancy without oncologist clearance. Severe kidney or liver dysfunction. Drug interactions: copper-chelating agents (penicillamine, trientine) reduce bioavailability by 60 to 80%. Zinc above 50 mg/day competes at copper transport sites. High-concentration topical vitamin C (15%+) chelates copper; separate application by two or more hours. Immunosuppressants may interact with the healing response; consult a prescriber. |
Key Differences
BPC-157 is a 15-amino-acid partial sequence of a protein isolated from human gastric juice [2]. GHK-Cu is a three-amino-acid peptide bound to copper and found in human plasma [5].
Each route carries its own evidence. Community users inject BPC-157 under the skin near an injury or take it by mouth for gut issues (community reports). FDA found no human study of BPC-157 by either route (FDA BPC-157 briefing). GHK-Cu goes on the skin in cosmetic products [7]. Many community users inject it instead (community reports). GHK-Cu's human trials tested skin products, so they say nothing direct about injecting it.
Human data are thin for BPC-157. FDA's 2026 review found five small human studies, with 2 to about 26 people each and about 80 in all. Two of the five exist only as meeting abstracts; the three published pilots cover about 30 people. FDA called the studies short and small, with doses likely exploratory (FDA BPC-157 briefing).
The 2025 review quoted on the BPC-157 card counted one clinical study, a knee-pain series. It took an orthopaedic sports medicine view and searched the literature to June 3, 2024 [1].
BPC-157's gut evidence is strongest in rats. In rats with surgical colon fistulas, BPC-157 given orally or intraperitoneally left fistulas about 40% smaller than controls from day 3 (FDA BPC-157 briefing). It also improved healing of bowel anastomoses in rats [4].
In people with gut disease, the evidence is one meeting abstract. It randomized 53 people with ulcerative colitis to a BPC-157 or placebo enema for two weeks, about half to each. A disease activity score fell 3.2 points on BPC-157 and 1.6 on placebo. The confidence interval for that gap crossed zero, and FDA found the evidence lacking (FDA BPC-157 briefing).
Oral use has no human data yet. FDA found no published human study or pharmacokinetic data for BPC-157 taken by mouth (FDA BPC-157 briefing). A 2015 phase 1 trial of BPC-157 tablets, with 42 volunteers planned, has posted no results (ClinicalTrials.gov NCT02637284). A rat study's authors describe BPC-157 as stable in human gastric juice [4].
BPC-157's tendon and blood-vessel effects are rat and cell findings. It sped the outgrowth and migration of rat tendon fibroblasts [2]. In rats with hind limb ischemia, it sped blood flow recovery and raised VEGFR2, a receptor that drives angiogenesis [3].
GHK-Cu's collagen and gene effects are lab findings too. It raised collagen synthesis in fibroblast cultures [5]. Its gene data come from the Connectivity Map, whose profiles were measured in five cancer cell lines, not in people [6].
GHK-Cu's human data are topical and mixed. In diabetic foot ulcers on the sole, a GHK-Cu gel closed a median 98.5% of ulcer area vs 60.8% on an inactive gel [8]. In a trial of 86 people with venous stasis ulcers, a 0.4% tripeptide-copper cream did no better than placebo [9]. After CO2 laser resurfacing in 13 patients, GHK-Cu products did no better than skin care without them on redness or wrinkles [10]. Patients using GHK-Cu did rate their skin quality higher.
So "BPC-157 for the gut, GHK-Cu for skin" compares different tiers of evidence. BPC-157's gut case is mostly rat studies plus one human enema abstract. GHK-Cu's skin case is small human trials of topical products, with mixed results.
Hair claims for GHK-Cu rest on community reports and lab work. A placebo-controlled trial in 45 men tested GHK combined with 5-aminolevulinic acid, not GHK-Cu alone. Hair counts rose more than on placebo over 6 months, with no difference in hair length or thickness [11].
No trial has set an injected dose for either peptide. Community tiers run BPC-157 at 250 to 500 mcg once or twice a day for 4 to 6 weeks. Injected GHK-Cu runs 1 to 3 mg a day for 4 to 8 weeks, and topical products run 1% to 3% without breaks (community reports). The same reports call 1 to 2 mg a day of injected GHK-Cu typical and note nausea above 1.5 mg a day.
Both promote angiogenesis in lab work, BPC-157 in rats [3] and GHK-Cu in lab studies [6]. Both profiles flag active cancer and pregnancy; GHK-Cu's also lists Wilson's disease and other copper disorders. Community reports flag anxiety with BPC-157, mostly above 500 mcg a day, and injection-site burning with GHK-Cu.
FDA saw no serious adverse events reported in the BPC-157 studies, but safety monitoring in most of them was unclear (FDA BPC-157 briefing). For injected GHK-Cu, FDA says there are limited human data to inform safety (FDA category 2 page).
Neither has an FDA approval. FDA's 2026 review found no approved BPC-157 product in any country (FDA BPC-157 briefing). Drugs@FDA lists no approved drug containing GHK-Cu (openFDA search, October 15, 2026). BPC-157 and injectable GHK-Cu sat in FDA's compounding category 2 until their nominators withdrew them (FDA category 2 page).
FDA's 2026 briefing proposed not adding BPC-157 to the 503A bulks list. Its advisory committee discussed BPC-157 on July 23, 2026, and FDA has posted no minutes (FDA July 2026 committee page). Non-injectable GHK-Cu was back on FDA's category 1, substances under evaluation, by May 14, 2026 (FDA 503A categories list). FDA plans a committee review of it before the end of February 2027.
WADA prohibits BPC-157 at all times, naming it under S0, non-approved substances (WADA 2026 list). The list doesn't name GHK-Cu. S0 also prohibits any pharmacological substance outside the list's other classes that lacks current government approval for human therapeutic use. Neither peptide appears in 21 CFR 216.23, the 503A bulks list.
When to Choose BPC-157
One injury site, such as a tendon or ligament (community practice injects near it; tendon data come from rats and rat cells)[2]
Gut symptoms are the target, knowing the gut data are mostly from rats (FDA BPC-157 briefing)
Human data beyond skin products matter to you (FDA counted five small BPC-157 studies, about 80 people, none by mouth or under the skin)
When to Choose GHK-Cu
Skin is the target and a topical product suits you (the human trials tested creams and gels)
Human wound-healing data matter to you (a gel helped diabetic foot ulcers; a copper cream failed in venous ulcers)[8][9]
Hair is a goal and community reports carry weight for you (no trial has tested GHK-Cu alone for hair loss)
Verdict
They don't compete on the same evidence. BPC-157's gut and tendon results come mostly from rats, plus about 80 people in five small studies (FDA BPC-157 briefing). GHK-Cu has small human trials of skin products, with one positive trial in diabetic foot ulcers [8] and mixed results elsewhere. Community reports favor BPC-157 for injuries and the gut, and GHK-Cu for skin and hair.
Research peptides with both sides of the evidence.
Published studies and community reports, side by side, for 150+ peptides. Save the ones you are weighing and see when anything changes.
Can You Stack BPC-157 + GHK-Cu?
Community protocols pair them for recovery, often with TB-500 in blends such as GLOW. No study has tested BPC-157 with GHK-Cu; a ClinicalTrials.gov search on October 15, 2026, found no registered trial of the pair. Both promote angiogenesis in lab work, and both profiles flag active cancer.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.
Related Comparisons
Related Guides & Stacks
Peptide Schedule Research TeamReviewed Oct 13, 202618 Citations
References
- [1]Emerging use of BPC-157 in orthopaedic sports medicine, systematic review: 36 studies, 35 preclinical and 1 clinical (Vasireddi et al., HSS J 2025) (opens in a new tab)PubMed (opens in a new tab)Review
- [2]BPC 157 and tendon healing: tendon outgrowth, cell survival and fibroblast migration, in rat tendon cells (Chang et al., J Appl Physiol 2011) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Pro-angiogenic BPC 157 and VEGFR2 activation, in rats and endothelial cells (Hsieh et al., J Mol Med 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]BPC 157 and healing of ileoileal anastomosis in rats (Vuksic et al., Surg Today 2007) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]GHK-Cu stimulates collagen synthesis in fibroblast cultures (Maquart et al., FEBS Lett 1988) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data, review (Pickart and Margolina, Int J Mol Sci 2018) (opens in a new tab)PubMed (opens in a new tab)Review
- [7]Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective, review (Mortazavi et al., BioImpacts 2025) (opens in a new tab)PubMed (opens in a new tab)Review
- [8]Topical GHK-Cu gel vs vehicle in diabetic neuropathic foot ulcers, multicenter randomized evaluator-blinded trial (Mulder et al., Wound Repair Regen 1994) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [9]Silver sulfadiazine vs a 0.4% tripeptide-copper cream vs placebo in 86 patients with venous stasis ulcers (Bishop et al., J Vasc Surg 1992) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [10]Topical GHK-Cu skin care after CO2 laser resurfacing, randomized, 13 patients completed (Miller et al., Arch Facial Plast Surg 2006) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [11]5-aminolevulinic acid and GHK complex vs placebo for male pattern hair loss, 45 patients, 6 months (Lee et al., Ann Dermatol 2016) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- FDA briefing document: BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (proposes not adding them to the 503A bulks list) (opens in a new tab)FDA Label
- ClinicalTrials.gov NCT02637284: PCO-02, oral BPC-157 tablets vs placebo in healthy volunteers, phase 1, 42 planned (status unknown since 2015, no results posted) (opens in a new tab)Clinical Trial
- FDA: bulk drug substances in compounding that may present significant safety risks, category 2 and nominated-but-withdrawn lists (current as of April 22, 2026) (opens in a new tab)FDA Label
- FDA: bulk drug substances nominated for 503A compounding, categories 1 to 3 (updated May 14, 2026; non-injectable GHK-Cu back in category 1) (opens in a new tab)FDA Label
- FDA: July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting page (non-binding recommendations; no minutes posted as of October 15, 2026) (opens in a new tab)FDA Label
- 21 CFR 216.23: bulk drug substances that can be used in 503A compounding (eCFR, current through October 13, 2026; last amended 2019) (opens in a new tab)FDA Label
- World Anti-Doping Agency, 2026 Prohibited List: BPC-157 under S0; thymosin beta-4 and TB-500 under S2.3; CJC-1295, sermorelin and ipamorelin under S2.2.4; prohibited at all times (opens in a new tab)Review